Azitra develops novel therapeutics to treat adverse skin conditions and disease using microbial and genetic engineering approaches for precision dermatology.

Azitra Inc

Azitra, Inc.

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.

Azitra

Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease. The Company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its programs in atopic dermatitis and targeted orphan indications. For more information visit www.azitrainc.com.

National Institutes of Health

National Science Foundation

U.S. Department of Defense

Bios Partners

Connecticut Innovations

Godfrey Capital

KdT Ventures

Leaps by Bayer

Sahsen Ventures

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

https://lnkd.in/eb2fzkQd

Azitra Inc (NYSE American: AZTR) Announces Pricing of $10.0 Million Public Offering. Maxim Group LLC is acting as the exclusive placement agent.

Read the full press release: https://lnkd.in/eiM4dhwu

Brad Hoffman, Danny Fossey, Robert Solomon, Stephen Polsinelli

Today, we're announcing the strengthening of our IP portfolio with a newly issued US patent and three additional patent allowances globally. 

Read more here:

https://lnkd.in/eNAB7rMF

We'll be at the Foundation for Foundation for Ichthyosis & Related Skin Types, Inc. (FIRST) conference this weekend to connect with patients and share about our clinical trial for Netherton syndrome at Azitra.

#FIRSTNC24 #NethertonSyndrome

We'll be at the Society of Investigative Dermatology this Friday in Dallas presenting new data on our platform and ATR-04

This Friday, we'll be presenting new data on our platform and Netherton syndrome program at ASGCT 2024. Stop by if you'll be there! 

https://lnkd.in/e_j2riaH

Today, we’re announcing the issuance of a new patent to strengthen our IP position and bolster our platform for precision dermatology.

https://lnkd.in/eMWwZqVn

AZTR

COM:AZITRAINC

Azitra

Last Close

0.47

22/11 21:00

Market Cap

3.16M

Beta: -

Volume Today

128.73K

Avg: -

name

homepage url

country

linkedin url

employee count

revenue

Description

investor of

Metrics